Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 2/2018

01-05-2018 | Original Article

Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy

Authors: D. G. Ribaldone, I. Dileo, R. Pellicano, A. Resegotti, S. Fagoonee, M. Vernero, G. Saracco, M. Astegiano

Published in: Irish Journal of Medical Science (1971 -) | Issue 2/2018

Login to get access

Abstract

Background

There is no agreeing if rescue therapy can avoid short-term colectomy in patients treated for severe steroid-refractory ulcerative colitis.

Aims

The aim of our study was to identify predictors of response to infliximab and cyclosporine A.

Methods

In this cross-sectional study, 49 patients with severe ulcerative colitis were included. Response to therapy was defined as three or more point reductions in Mayo score after 6 months of treatment and avoidance of colectomy after 1 year. The predictors analysed were gender, age, time from ulcerative colitis diagnosis, months of steroid or/and azathioprine therapy before onset of the severe phase, smoking habits, extension of the disease, laboratory analyses and Mayo score.

Results

Patients treated with infliximab showed a statistically significant higher response rate in case of moderate Mayo score (P = 0.04). Ex-smokers had very low chance of response to infliximab (P = 0.03). In the group treated with cyclosporine A, patients with C-reactive protein >3 mg/L had a response rate significantly higher than those with C-reactive protein <3 mg/L (P = 0.03); those with negative C-reactive protein and moderate Mayo score did not responded to therapy, while in the ones with elevated C-reactive protein and/or severe Mayo score, 15 versus 4 responded (P = 0.008).

Conclusions

Our data suggest that cyclosporine A is advisable in ex-smokers. In never smokers or active smokers, infliximab can be prescribed in case of Mayo score ≤10 and/or negative CRP, while cyclosporine A is indicated in case of Mayo score >10 and positive CRP.
Literature
1.
go back to reference Dignass A, Eliakim R, Magro F et al (2012) European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 6:965–990CrossRefPubMed Dignass A, Eliakim R, Magro F et al (2012) European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 6:965–990CrossRefPubMed
2.
go back to reference Peyrin-Biroulet L, Panés J, Sandborn WJ et al (2016) Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol 14:348–354.e17CrossRefPubMed Peyrin-Biroulet L, Panés J, Sandborn WJ et al (2016) Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol 14:348–354.e17CrossRefPubMed
4.
go back to reference Actis GC, Pellicano R (2016) The pathologic galaxy modulating the genotype and phenotype of inflammatory bowel disease: co-morbidity, contiguity, and genetic and epi-genetic factors. Minerva Med 107:401–412PubMed Actis GC, Pellicano R (2016) The pathologic galaxy modulating the genotype and phenotype of inflammatory bowel disease: co-morbidity, contiguity, and genetic and epi-genetic factors. Minerva Med 107:401–412PubMed
5.
go back to reference Etchevers MJ, Aceituno M, Garcia-Bosch O et al (2009) Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis 9:1320–1325CrossRef Etchevers MJ, Aceituno M, Garcia-Bosch O et al (2009) Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis 9:1320–1325CrossRef
6.
go back to reference Tremaine WJ, Sandborn WJ (1999) Practice guidelines for inflammatory bowel disease: an instrument for assessment. Mayo Clin Proc 74:495–501CrossRefPubMed Tremaine WJ, Sandborn WJ (1999) Practice guidelines for inflammatory bowel disease: an instrument for assessment. Mayo Clin Proc 74:495–501CrossRefPubMed
7.
go back to reference Travis SP, Stange EF, Lémann M et al (2008) European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2:24–62CrossRefPubMed Travis SP, Stange EF, Lémann M et al (2008) European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2:24–62CrossRefPubMed
8.
go back to reference Bennis M, Tiret E (2012) Surgical management of ulcerative colitis. Langenbeck's Arch Surg 397:11–17CrossRef Bennis M, Tiret E (2012) Surgical management of ulcerative colitis. Langenbeck's Arch Surg 397:11–17CrossRef
9.
go back to reference Koltun WA (2009) Role of medical rescue therapy in the management of acute severe ulcerative colitis: the surgical perspective. Expert Rev Gastroenterol Hepatol 3:325–327CrossRefPubMed Koltun WA (2009) Role of medical rescue therapy in the management of acute severe ulcerative colitis: the surgical perspective. Expert Rev Gastroenterol Hepatol 3:325–327CrossRefPubMed
10.
go back to reference Campbell S, Travis S, Jewell D (2005) CyclosporineA use in acute ulcerative colitis: a long-term experience. Eur I Gastroenterol Hepatol 17:79–84CrossRef Campbell S, Travis S, Jewell D (2005) CyclosporineA use in acute ulcerative colitis: a long-term experience. Eur I Gastroenterol Hepatol 17:79–84CrossRef
11.
go back to reference Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476CrossRefPubMed Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476CrossRefPubMed
12.
go back to reference Van Assche G, Vermeire S, Rutgeerts P (2011) Management of acute severe ulcerative colitis. Gut 60:130–133CrossRefPubMed Van Assche G, Vermeire S, Rutgeerts P (2011) Management of acute severe ulcerative colitis. Gut 60:130–133CrossRefPubMed
13.
go back to reference Lees CW, Heys D, Ho GT et al (2007) A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 26:411–419CrossRefPubMed Lees CW, Heys D, Ho GT et al (2007) A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 26:411–419CrossRefPubMed
14.
go back to reference Mocciaro F, Renna S, Orlando A et al (2012) Cyclosporine A or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. J Crohns Colitis 6:681–686CrossRefPubMed Mocciaro F, Renna S, Orlando A et al (2012) Cyclosporine A or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. J Crohns Colitis 6:681–686CrossRefPubMed
15.
go back to reference Actis GC, Fadda M, David E et al (2007) Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 7:13CrossRefPubMedPubMedCentral Actis GC, Fadda M, David E et al (2007) Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 7:13CrossRefPubMedPubMedCentral
16.
go back to reference Pinna-Pintor M, Arese P, Bona R et al (2000) Severe steroid-unresponsive ulcerative colitis: outcomes of restorative proctocolectomy in patients undergoing cyclosporin treatment. Dis Colon Rectum 43:609–613CrossRefPubMed Pinna-Pintor M, Arese P, Bona R et al (2000) Severe steroid-unresponsive ulcerative colitis: outcomes of restorative proctocolectomy in patients undergoing cyclosporin treatment. Dis Colon Rectum 43:609–613CrossRefPubMed
18.
go back to reference Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625–1629CrossRefPubMed Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625–1629CrossRefPubMed
19.
go back to reference Subramaniam K, Richardson A, Dodd J et al (2014) Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Intern Med J 44:464–470CrossRefPubMed Subramaniam K, Richardson A, Dodd J et al (2014) Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Intern Med J 44:464–470CrossRefPubMed
20.
go back to reference Aratari A, Papi C, Clemente V et al (2008) Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis 40:821–826CrossRefPubMed Aratari A, Papi C, Clemente V et al (2008) Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis 40:821–826CrossRefPubMed
21.
go back to reference Nuij V, Fuhler GM, Edel AJ et al (2015) Benefit of earlier anti-TNF treatment on IBD disease complications? J Crohns Colitis 9:997–1003CrossRefPubMed Nuij V, Fuhler GM, Edel AJ et al (2015) Benefit of earlier anti-TNF treatment on IBD disease complications? J Crohns Colitis 9:997–1003CrossRefPubMed
Metadata
Title
Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy
Authors
D. G. Ribaldone
I. Dileo
R. Pellicano
A. Resegotti
S. Fagoonee
M. Vernero
G. Saracco
M. Astegiano
Publication date
01-05-2018
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 2/2018
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-017-1666-0

Other articles of this Issue 2/2018

Irish Journal of Medical Science (1971 -) 2/2018 Go to the issue